BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Smith+Nephew launches new tool in India for use in primary and revision hip arthroplasty

18 August 2023 | News

Features proprietary OXINIUM DH material; eliminates Cobalt Chrome alloy reducing wear and corrosion risks



UK-based medtech firm Smith+Nephew has announced the launch of its OR3O Dual Mobility System for use in primary and revision hip arthroplasty in India. Compared with traditional solutions, dual mobility implants have a small diameter femoral head that locks into a larger polyethylene insert - increasing stability, reducing dislocation risk, and offering improved range of motion.

While most hip implants utilise a Cobalt Chrome (CoCr) liner along with CoCr/SST or ceramic head balls, OR3O incorporates Smith+Nephew's latest advanced bearing surface, OXINIUM DH, for its liner and proprietary OXINIUM on XLPE for its femoral head and polyethylene inserts. This eliminates both the modular CoCr liner and/or CoCr head ball from the construct - reducing wear and corrosion risks that have been associated with the alloy.

OXINIUM DH (Diffusion Hardened) is a unique variation of Smith+Nephew's OXINIUM Technology platform that increases the depth of hardening through an additive manufacturing process.

The modular dual mobility segment was introduced to India in 2015 and has continued to grow globally. Post-operative dislocation is the second most common reason for revision of a total hip replacement globally and remains a serious concern for surgeons when performing total hip arthroplasty. Studies have shown dual mobility is uniquely positioned to manage dislocation, better than metal-on-metal or ceramic-on-ceramic large head series.

Smith+Nephew's OR3O Dual Mobility System is available in India for both primary and revision applications and offers cross-compatibility with the R3 Acetabular System.

Image caption- L-R- Kamesh Teng (Sr. Director, Orthopedics, S+N India) and Damien Ben-L'Amri (Sr. Director, Orthopedics, S+N Asia-Pacific)